Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00225732




Registration number
NCT00225732
Ethics application status
Date submitted
22/09/2005
Date registered
26/09/2005
Date last updated
22/06/2016

Titles & IDs
Public title
Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients
Scientific title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Pain in the Post-Operative Adult Patients
Secondary ID [1] 0 0
CPI-CL-008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Normal saline as placebo comparator
Treatment: Drugs - Intravenous ibuprofen

Active Comparator: intravenous ibuprofen -

Placebo Comparator: normal saline -


Other interventions: Normal saline as placebo comparator
250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)

Treatment: Drugs: Intravenous ibuprofen
800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.
Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery
Timepoint [1] 0 0
24 Hours

Eligibility
Key inclusion criteria
1. Scheduled for elective abdominal hysterectomy surgery with anticipated need for
post-operative I.V. morphine analgesia with anticipated use of = 24 hours.

2. Adequate IV access

3. Anticipated hospital stay = 24 hours
Minimum age
18 Years
Maximum age
70 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Be unable to make a reliable self-report of pain intensity to pain relief

2. Less than 18 years of age

3. Greater than 70 years of age

4. Use of NSAIDs within 12 hours prior to dosing

5. Use of analgesics, muscle relaxants and sedatives less than 24 hours prior to CTM
administration with the following exceptions: paracetamol (acetaminophen) can be
administered until 6 hours prior to surgery; tramadol can be administered until
midnight the evening prior to surgery; muscle relaxants working at the neuromuscular
junction used for intubation and/or anesthesia administration for the surgical
procedure prior to CTM administration; and sedatives (i.e., midazolam) used as a
co-induction agent for the surgical procedure prior to CTM administration

6. Patients taking warfarin, lithium, combination of ACE-inhibitors and furosemide

7. Patients with anemia (active clinically significant) and/or a history or evidence of
asthma or heart failure

8. History of allergy or hypersensitivity to any component of Caldolor, aspirin (or
aspirin related products), NSAIDs, or COX-2 inhibitors

9. Pregnant or nursing

10. History of severe head trauma that required current hospitalization, intracranial
surgery or stroke within the previous 30 days, or any history of intracerebral
arteriovenous malformation, cerebral aneurysm or CNS mass lesion

11. Weigh less than 30kg

12. Have a history of congenital bleeding diathesis (eg hemophilia) or any active
clinically significant bleeding, or have underlying platelet dysfunction including
(but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular
coagulation, or congenital platelet dysfunction

13. Have GI bleeding that required medical intervention within the previous 6 weeks
(unless definitive surgery has been performed)

14. Have a platelet count less than 30,000mm3 determined within the 28 days prior to
surgery

15. Pre-existing dependence on narcotics or known tolerance to opioids

16. Inability to understand the requirements of the study, be willing to provide written
informed consent (as evidenced by signature on an informed consent document approved
by an Institutional Review Board [IRB]), and agree to abide by the study restrictions
and to return for the required assessments

17. Refusal to provide written authorization for use and disclosure of protected health
information

18. Be on dialysis, have oliguria or calculated creatinine clearance of less than 60
mL/min (calculated using the Cockcroft and Gault formula) determined within the 28
days prior to surgery

19. Inability to achieve hemostasis or inability to close surgical incision, prior to
Operating Room discharge

20. Operative procedure includes organ transplant

21. Pre or intra-operative procedure utilized for the prevention of pre- or post-operative
pain (i.e. epidural or nerve blocks)

22. Be receiving full dose anticoagulation therapy or Activated Protein C within 6 hours
before dosing (Prophylaxis with subcutaneous heparin is acceptable)

23. Have received another investigational drug within the past 30 days

24. Be otherwise unsuitable for the study in the opinion of the investigator

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2008
Sample size
Target
Accrual to date
Final
319
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Cumberland Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study of Caldolor (IV ibuprofen) administered to post-operative
hospitalized adult patients every 6 hours for 48 hours is to determine the efficacy of
Caldolor compared to placebo for the treatment of post-operative pain as measured by
reduction in the requirement for the narcotic analgesic, morphine, post surgery
Trial website
https://clinicaltrials.gov/ct2/show/NCT00225732
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00225732